Form 4: Ionis Pharmaceuticals Executive Sells Shares After Performance-Based Stock Units Vest

C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, sold 1,327 shares of common stock after the vesting of performance-based restricted stock units.

Summary

• C. Frank Bennett, the EVP and Chief Scientific Officer of Ionis Pharmaceuticals, reported transactions involving the company's common stock.
• On January 30, 2025, Bennett acquired 3,607 shares upon the vesting of performance-based restricted stock units (PRSUs).
• The vesting was based on the company's relative total shareholder return compared to a peer group, resulting in a 150% payout of target shares.
• On January 31, 2025, Bennett sold 1,327 shares at a weighted average price of $32.4636.
• Following these transactions, Bennett beneficially owns 93,146 shares of Ionis Pharmaceuticals.

Sentiment

Score: 6

Explanation: The document itself is neutral, reporting a routine executive stock transaction. The vesting of PRSUs suggests positive performance, but the subsequent sale introduces a slightly negative element, resulting in a moderately positive sentiment.

Positives

• The vesting of PRSUs at 150% indicates strong performance relative to peers based on total shareholder return.

Negatives

• The sale of 1,327 shares by a key executive could be interpreted negatively by some investors, although it's a small portion of their holdings.

Risks

• Executive stock sales can sometimes signal a lack of confidence, although this sale appears to be a small portion of the executive's holdings after a vesting event.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The vesting of performance-based equity indicates that the company met certain pre-defined goals, which is generally a positive sign. However, subsequent sales are often driven by personal financial planning and diversification strategies.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity to align management's interests with those of shareholders.
• Vesting schedules and performance metrics vary across companies and industries.
• Comparing Ionis Pharmaceuticals' executive compensation structure and performance metrics to those of its peers (e.g., Alnylam Pharmaceuticals, Sarepta Therapeutics) would provide a more comprehensive assessment.

Stakeholder Impact

• The vesting of PRSUs and subsequent stock sale have a minor impact on shareholders.
• The vesting reflects the company's performance, which benefits shareholders.
• The stock sale could slightly dilute the value of existing shares, but the effect is likely minimal.

Key Dates